Irritable Bowel Syndrome Evaluation and Treatment in Primary Care

Irritable Bowel Syndrome Clinical Trial

Official title:

Irritable Bowel Syndrome Evaluation and Treatment in Primary Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01641341
• Other study ID #: 10-108
• Status: Completed
• Phase: Phase 4
• Start date: November 2010
• Est. completion date: March 2012

Study information

• Verified date: January 2019
• Source: American Academy of Family Physicians
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Overview of Methods: This is a double blind, randomized controlled trial with a non-balanced randomization and a cross-over to active treatment for placebo treated individuals who do not respond to the placebo treatment. Data collected will help determine the feasibility of the study design in primary care offices. Patient outcome data will provide a more precise estimate of power for a larger, classic randomized trial to determine if such a study can be reasonably undertaken within primary care practices.

Aims: The aims of this pilot study are to: 1) Evaluate how well Genova Diagnostics (GDx) IBS tests can be integrated into primary care, 2) examine the effects of the Genova Diagnostics (GDx) test on treatment, and 3) observe and track patients' health, quality of life and clinical outcomes related to IBS during the study period.

Description:

This study will take place in 8 practices which are members of the AAFP NRN. Eligible practices must be able to identify at least 25 active patients (seen in last 24 months) with a diagnosis of IBS from billing or electronic health record data to be eligible to participate. Each practice will be asked to recruit 10 patients.

Adult patients identified by their physician as having IBS symptoms will be termed "potentially eligible patients" and will be invited into the study via personal invitation when presenting at the practice on a regularly-scheduled visit, by letters mailed to these patients on practice letterhead and signed by the physician, or through phone contact with a member of the practice.

If a patient agrees to participate in the study, s/he will be asked to read and sign an initial informed consent. Consent forms will be included with the letters mailed to patients, and additional copies of the consent will be kept at the practice. The initial informed consent will cover consent for stool testing, for collection of all study outcome data including new diagnoses uncovered by the stool testing and any follow up procedures that are conducted as a result of the stool test results. This initial consent will indicate that based on stool testing results the patient may be referred for more evaluation or open label treatment from their physician or may be recommended for one or more study directed treatment(s).

Once the stool tests have returned the patient will be contacted to review these results. At that time the patient will be asked to sign a secondary consent form if study directed therapy is recommended. This consent form or these consent forms (if more than one therapy is recommended) will be treatment specific and explain that the patient will be randomized to active or placebo treatment in a double blinded fashion, that the patient will be crossed over to either active treatment or placebo after 8 weeks and that all patients will be offered active treatment by the end of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 61
• Est. completion date: March 2012
• Est. primary completion date: March 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• between the ages of 18 and 65 years of age

• meet Rome III criteria for IBS

• willing to complete surveys and daily symptom logs for three to four 14-day periods

• have positive symptoms for at least 3 days out of the 14 days of the baseline daily log records

Exclusion Criteria:

• have HIV or AIDs

• have gall stones with a gall bladder present

Related Conditions & MeSH terms

• Irritable Bowel Syndrome
• Syndrome

Intervention

Drug:
• Bifidobacterium infantis
once a day for seven to eight weeks
• Pancrelipase
Pancrelipase (one capsule prior to meals or snacks)
• Nitazoxanide
Nitazoxanide (500mg twice a day for 7 days)
• Placebo
Placebo capsule will not contain active treatment ingredients.

Locations

Country	Name	City	State
United States	Baton Rouge Family Practice	Baton Rouge	Louisiana
United States	Southwest Family Medicine Associates	Dallas	Texas
United States	American Academy of Family Physicians-National Research Network	Leawood	Kansas
United States	Overland Park Family Health Partners	Leawood	Kansas
United States	Torrance Clinical Research	Lomita	California
United States	Raj Kachoria	Macedon	New York
United States	Silver Sage Center for Family Medicine	Reno	Nevada
United States	Family Medicine of SE Missouri	Sikeston	Missouri
United States	Missouri Delta Physician Services	Sikeston	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
American Academy of Family Physicians	Genova Diagnostics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	A reduction in IBS symptoms	20 to 40% of the control/placebo patients and approximately 70-75% of the treatment patients will experience a positive outcome as determined by both the daily log sheets and the modified Rome criteria administered at baseline, 8 and 16 weeks.	16 weeks